New pain drug HRS-2129 tested in healthy adults
NCT ID NCT06742840
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 1 study tested the safety and tolerability of HRS-2129, a new drug for pain, in 23 healthy adults aged 18 to 55. Researchers measured side effects and how the body processes the drug, along with pain responses to cold and heat. Because it was only in healthy volunteers, it does not yet show if the drug helps people with chronic pain.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-2129
What this could lead to
If successful, this could point toward a new pain treatment option.
What could go wrong
This is an early Phase 1 study in healthy people, not patients. It only tests safety and basic pain response, so it may not work for real pain conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Third Xiangya Hospital of Central South University
Changsha, Hunan, 410013, China